2025年12月12日,吉利德与Arcus Biosciences联合宣布,其PD-1+TIGIT+化疗一线治疗胃癌的三期临床STAR-221因无效而终止。这是TIGIT抗体赛道又一次重大挫折,也再次引发业界对免疫联合疗法靶点选择与临床策略的深刻反思。在看似火热的肿瘤免疫战场,科学与商业的博弈从未停止。TIGIT抗体困局,为何屡战屡败?TIGIT是免疫检查点分子,业界期望它与PD - 1等协同激活...
Source Link2025年12月12日,吉利德与Arcus Biosciences联合宣布,其PD-1+TIGIT+化疗一线治疗胃癌的三期临床STAR-221因无效而终止。这是TIGIT抗体赛道又一次重大挫折,也再次引发业界对免疫联合疗法靶点选择与临床策略的深刻反思。在看似火热的肿瘤免疫战场,科学与商业的博弈从未停止。TIGIT抗体困局,为何屡战屡败?TIGIT是免疫检查点分子,业界期望它与PD - 1等协同激活...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.